Genomic testing in high-grade serous ovarian cancer: current options and future development

被引：0
|
作者：
Devlin, Michael-John [1 ,2 ]
Miller, Rowan [2 ,3 ,4 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, London, England
[2] St Bartholomews Hosp, Dept Med Oncol, London, England
[3] Univ Coll London Hosp, Dept Med Oncol, London, England
[4] Univ Coll London Hosp NHS Fdn Trust, Med Oncol, London NW1 2PG, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / 03期
关键词：
Medical Oncology; Ovary; Cystadenocarcinoma; Serous; HOMOLOGOUS RECOMBINATION DEFICIENCY; OLAPARIB MAINTENANCE THERAPY; MISMATCH REPAIR DEFICIENCY; REVERSION MUTATIONS; PARP INHIBITORS; DNA-REPAIR; PLATINUM; BRCA; SENSITIVITY; MECHANISM;
D O I：
10.1136/ijgc-2022-003702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Understanding the genomic complexity of high-grade serous ovarian cancer is now essential in guiding patient management, particularly in the first-line setting. Our knowledge in this area has expanded rapidly in recent years, with biomarkers developing in parallel to agents designed to exploit cancer-associated genetic aberrations. In this review we will take stock of the current landscape of genetic testing and look towards the future with developments that aim to refine personalized treatment paradigms and track treatment resistance in real time.
引用
收藏
页码：358 / 363
页数：6
相关论文
共 50 条
  • [1] Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
    Gadducci, Angiolo
    Guarneri, Valentina
    Peccatori, Fedro Alessandro
    Ronzino, Graziana
    Scandurra, Giuseppa
    Zamagni, Claudio
    Zola, Paolo
    Salutari, Vanda
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [2] Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
    Kieffer, Yann
    Bonneau, Claire
    Popova, Tatiana
    Rouzier, Roman
    Stern, Marc-Henri
    Mechta-Grigoriou, Fatima
    FRONTIERS IN GENETICS, 2020, 11
  • [3] Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
    Hillman, R. Tyler
    Chisholm, Gary B.
    Lu, Karen H.
    Futreal, P. Andrew
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (03): : 265 - 272
  • [4] BRCA gene testing in women with high-grade serous ovarian carcinoma
    Kansu, Bengi
    Gardner, Jennifer
    Price-Tate, Rachel
    Murch, Oliver
    Murray, Alex
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 41 (06) : 962 - 965
  • [5] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
    Freimund, Alison E.
    Beach, Jessica A.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +
  • [6] The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
    Yan, Shunfei
    Frank, Daniel
    Son, Jinbae
    Hannan, Katherine M.
    Hannan, Ross D.
    Chan, Keefe T.
    Pearson, Richard B.
    Sanij, Elaine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (01):
  • [7] Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma
    Bromley, Amy B.
    Altman, Alon D.
    Chu, Pamela
    Nation, Jill G.
    Nelson, Gregg S.
    Ghatage, Praful
    Kalloger, Steve E.
    Han, Guangming
    Koebel, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (05) : 397 - 404
  • [8] Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
    Li, Yuan
    Zhang, Xiaolan
    Gao, Yan
    Shang, Chunliang
    Yu, Bo
    Wang, Tongxia
    Su, Junyan
    Huang, Cuiyu
    Wu, Yu
    Guo, Hongyan
    Ha, Chunfang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [9] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [10] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
12345